Antihypertensive activity of 2-amino-4-(3,4-dichlorophenyl)-2-imidazoline (MJ 10459-2) and catecholamine reduction.
Antihypertensive activity of 2-amino-4-(3,4-dichlorophenyl)-2-imidazoline hydrobromide (MJ 10459-2) was assessed in conscious, spontaneously hypertensive and stress-induced hypertensive rats via indirect determination of systolic blood pressure. Subcutaneous administration of 1-4 mg/kg resulted in lowering of blood pressure that was dose related. No reductions in the content of norepinephrine, dopamine, serotonin or 5-hydroxyindoleacetic acid were noted in the cerebrum, cerebellum, midbrain or medulla/pons area of brain after 1 and 4 mg/kg of MJ 10459-2. Cardiac tissue norepinephrine was reduced to 4-6% of control values after subcutaneous doses of 0.2-20 mg/kg of MJ 10459-2 in hypertensive and normotensive rats. These data suggest that at least part of the blood pressure lowering effects of MJ 10459-2 may involve reduction of peripheral noradrenergic stores.
D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism*; D002722:Chlorobenzenes / Q000494:pharmacology / Q000627:therapeutic use; D003864:Depression, Chemical; D004298:Dopamine / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D013312:Stress, Physiological / Q000150:complications; D013997:Time Factors
D000959:Antihypertensive Agents; D002395:Catecholamines; D002722:Chlorobenzenes; D007093:Imidazoles; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D004298:Dopamine; D009638:Norepinephrine